Entera Bio completed a market-priced private placement, raising approximately $275 million at $2.04 per share through a mix of ordinary shares and pre-funded warrants. The offering closed on Jul 28, 2026, with 122,961,215 shares and 11,842,695 pre-funded warrants issued, and includes BVF board designation rights tied to ownership thresholds. The company also signed a Registration Rights Agreement committing to file a resale registration within 30 days and pursue rapid effectiveness, supporting investor liquidity. Proceeds are earmarked to initiate the Phase 3 registrational study of EB613 in postmenopausal osteoporosis and for general corporate purposes.
Agreement 1: Entera Bio Raises $275 Million in Market-Priced Private Placement Led by BVF
- Agreement type: Securities Purchase Agreement for private placement of ordinary shares and pre-funded warrants
- Counterparty: Institutional and accredited investors led by BVF Partners
- Signed / Effective: Jul 26 2026 / Jul 28 2026
- Duration / Termination: At will
- Reason: Fund Phase 3 EB613 and general corporate purposes
Agreement 2: Entera Bio Signs Registration Rights Agreement to Enable Resale After $275 Million Financing
- Agreement type: Registration Rights Agreement for resale of shares and warrant shares
- Counterparty: Investors led by BVF Partners
- Signed / Effective: Jul 28 2026 / Jul 28 2026
- Duration / Termination: At will
- Reason: Facilitate investor liquidity post-financing
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.